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background:  Vitamin E (Vit E) deficiency may cause neurological dysfunction, myopathies, and diminished erythrocyte life span. As a 
significant proportion of circulating Vit E is found in apo B-containing lipoproteins, we investigated the effects of evolocumab (AMG 145), a 
fully human monoclonal antibody to PCSK9 that markedly lowers LDL-C, on Vit E concentrations.
Methods:  In DESCARTES, patients on NCEP ATP III risk-based optimized lipid-lowering therapy were randomized 2:1 to 52 weeks 
of subcutaneous monthly evolocumab 420 mg or placebo. In this sub-study (n = 100), we measured Vit E (α + γ tocopherol) in serum, 
lipoprotein fractions (HDL and LDL), and red cell membranes (RCM; a surrogate of tissue levels) using ultra performance liquid 
chromatography. Serum and lipoprotein measurements were normalized for cholesterol concentration while RCM measurements were 
normalized for hematocrit. Patients receiving Vit E supplements were excluded from the analysis.
Results:  Within the full analysis set, evolocumab reduced LDL-C by 57% and increased HDL-C by 5.4% from baseline vs placebo. In 
evolocumab-treated patients not receiving Vit E supplements (n = 44), serum and LDL Vit E levels decreased; in parallel with the decrease 
in LDL-C, HDL Vit E levels increased modestly. RCM and normalized Vit E levels showed no change (Table). Results did not differ in 
patients with a post baseline LDL-C < 25 mg/dL.
conclusion:  Evolocumab lowers LDL-C markedly but does not lower Vit E concentrations within lipoproteins or RCM. 
